Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CMMB
- Price
- 1.51
- Stock movement up
- +- (0.00%)
- Company name
- Chemomab Therapeutics Ltd DRC
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 9.29M
- Ent value
- 3.46M
- Price/Sales
- -
- Price/Book
- 0.83
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -23.29%
- 1 year return (CAGR)
- -95.23%
- 3 year return (CAGR)
- -64.72%
- 5 year return (CAGR)
- -83.25%
- 10 year return (CAGR)
- -
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CMMB does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.83 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 6.16M |
| EPS (TTM) | -1.63 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -33.69K |
| Operating income (TTM) | -10.81M |
| Net income (TTM) | -10.09M |
| EPS (TTM) | -1.63 |
| EPS (1y forward) | -0.20 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.97M |
| Net receivables | 1.72M |
| Total current assets | 11.93M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 188.00K |
| Total assets | 12.37M |
| Accounts payable | 194.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.14M |
| Total liabilities | 1.14M |
| Shareholder's equity | 11.23M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -89.80% |
| Return on Assets | -81.54% |
| Return on Invested Capital | -89.80% |
| Cash Return on Invested Capital | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.55 |
| Daily high | 1.55 |
| Daily low | 1.45 |
| Daily Volume | 70K |
| All-time high | 38092.80 |
| 1y analyst estimate | 17.50 |
| Beta | 0.59 |
| EPS (TTM) | -1.63 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| CMMB | S&P500 | |
| Current price drop from All-time high | -100.00% | -1.82% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 5 Feb 2026 | 9 Mar 2009 |
| Avg drop from high | -91.43% | -10.84% |
| Avg time to new high | 441 days | 12 days |
| Max time to new high | 1760 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
9.29M
Marketcap category
Small-cap
Description
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page